Navigation Links
The Results From a Clinical Trial Led by the Montreal Heart Institute Demonstrate That Drug Reduces Inflammation in Patients With Serious Cardiovascular Disease
Date:11/10/2008

MONTREAL, Nov. 10 /PRNewswire/ -- Montreal Heart Institute Research Centre Director Dr. Jean-Claude Tardif presented yesterday results from a clinical trial demonstrating that VIA-2291, an investigational drug being developed by VIA Pharmaceuticals, Inc., significantly inhibited production of leukotrienes, proposed mediators of vascular inflammation, in patients with serious heart disease. VIA-2291 was well-tolerated with no serious adverse events attributed to the drug. The study was presented in a Special Session at the American Heart Association 2008 Scientific Sessions in New Orleans, Louisiana.

The study of VIA-2291 was designed to establish optimal dosing and safety data in patients with acute coronary syndromes (ACS), who recently had a heart attack or unstable angina. 191 patients were treated once daily for 12 weeks with one of three dose levels of VIA-2291 or placebo. A sub-study of patients continued for an additional 12 weeks of treatment.

Cardiologists have several therapies that help reduce heart disease risk factors, but none that specifically target inflammation, an underlying cause of atherosclerosis, which leads to major adverse cardiac events (MACE), including heart attack and stroke.

VIA-2291 is designed to be a selective and reversible inhibitor of 5-LO, a key enzyme in the biosynthesis of leukotrienes, that are important mediators of inflammation believed to be involved in the development and progression of atherosclerosis.

"VIA-2291 has the potential to be the first drug to specifically target one cardiovascular inflammatory pathway," said Dr. Jean-Claude Tardif, the VIA-2291 ACS trial's principal investigator, director of the Montreal Heart Institute Research Centre and professor of medicine at the Universite de Montreal. "These data support further clinical development of this drug, including larger outcome trials."

Study Results

The trial demonstrated a statistically significant, dose-depende
'/>"/>

SOURCE Montreal Heart Institute
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Chindex International Inc. Reports Second Quarter FY 2009 Financial Results
2. Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2008 and Updates 2008 Full Year Guidance
3. MGT Capital Investments Reports Third Quarter 2008 Financial Results and Provides Update on Recent Developments
4. China Sky One Medical, Inc. Announces Record Third Quarter 2008 Results
5. Ellex Announces Six-Month Results on Retina Regeneration Therapy
6. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2008 Financial Results on Tuesday, November 11, at 8:30 A.M. EST
7. InfoLogix to Report Third Quarter Financial Results on November 10, 2008
8. Transition Therapeutics to Hold Conference Call on First Quarter Fiscal 2009 Financial Results on Monday, November 10th, at 4:30 P.M. EST
9. China Pharma Holdings, Inc. Reports Third Quarter 2008 Financial Results and Corporate Updates
10. Fraxel(R) Laser Systems Shown to Provide Superior Results Compared to Pseudo Fractional Laser Technologies
11. NutraCea Announces Third Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... 2014 Gersowitz Libo & Korek, P.C., a ... national Tier recognition in the 2015 Edition of U.S. News-Best ... signals a unique combination of quality law practice and breadth ... this honor and especially grateful to our clients whose continued ... ranking possible,” said Jeff S. Korek, senior partner at ...
(Date:11/23/2014)... a well-known wedding dress manufacturer, has unveiled its new collection ... now offered at deeply discounted prices, up to 75 percent ... 15. The main purpose of the promotion is to expand ... are ideal options for ladies who are eager to look ... new mint cocktail dresses are very beautiful; they are made ...
(Date:11/23/2014)... Pro Ace Care, a renowned Vancouver hot water ... providing an 8 year warranty on its selected hot water ... up due to the impending winter season, it was important ... premium service that the company provides. As a result, Pro ... Wood and Bradford hot water tanks. , “Every installer ...
(Date:11/23/2014)... Locks-Magnetic.com, a notable magnetic locks maker, has released a ... are available at low rates up to 30% off. ... new emergency doors. The emergency door adopts fireproof material ... several colors. All of the products are top-quality guaranteed. ... not as easy as many people think. As ...
(Date:11/23/2014)... (PRWEB) November 23, 2014 More than ... month in a federal litigation involving Byetta lawsuits ( ... medications, Bernstein Liebhard LLP reports. , A Case ... over a class of Type 2 diabetes medications referred ... the U.S. District Court, Southern District of California, where ...
Breaking Medicine News(10 mins):Health News:U.S. News-Best Lawyers “Best Law Firms” Names Gersowitz Libo & Korek P.C. a 2015 Tier 1 Ranking Firm 2Health News:Trendy Long Black Evening Gowns Now Provided By iFitDress.com 2Health News:Pro Ace Care Now Gives 8 Year Guarantee on Selected Vancouver Hot Water Tanks 2Health News:California Federal Court Overseeing Byetta Lawsuits, Other Incretin Mimetic Claims Adds New Cases in November, Bernstein Liebhard LLP Reports 2Health News:California Federal Court Overseeing Byetta Lawsuits, Other Incretin Mimetic Claims Adds New Cases in November, Bernstein Liebhard LLP Reports 3Health News:California Federal Court Overseeing Byetta Lawsuits, Other Incretin Mimetic Claims Adds New Cases in November, Bernstein Liebhard LLP Reports 4
... President, Corporate Development and, Senior Vice ... N.J., Sept. 11 Pharmacopeia,(Nasdaq: PCOP ), ... novel,small molecule therapeutics, today announced the appointments of ... and S. David,Kimball, Ph.D., as Senior Vice President, ...
... 11 Vista Partners announced today,that it has ... ).,Ross Silver, Director of Research for Vista Partners ... I trials. We were,particularly encouraged by activity in ... been approved for use in this difficult to ...
... XI,AN, China, Sept. 11 /Xinhua-PRNewswire-FirstCall/ -- China,Bionanometer Industries ... the bionanometer industry, has recently promoted a new,series ... a year of scientific verification, research and experiments. ... dream, and therefore the product,line,s name means -- ...
... Health Card Systems, Inc. (Nasdaq: NMHC ), a ... for the fiscal,fourth quarter and fiscal year ended June ... Revenue for the 2007 fiscal fourth quarter was ... the same period last year, a 31.0,percent decrease. This ...
... Stop Severe Bleeding, BETHESDA, Md., Sept. 10 ... high-pressure,bleeding in moderate to severe wounds has received FDA ... good news for soldiers,and civilians alike, because the product ... spot. "The FDA,s speedy approval of WoundStat means ...
... Sept. 10 The Blue Cross and Blue,Shield ... Department of Health Care Policy, announced today seven ... BlueWorks(R) winners, in the,category of ,Collaborating with Providers., ... the Harvard Medical School,Department of Health Care Policy ...
Cached Medicine News:Health News:Pharmacopeia Announces Senior Additions to Management Team 2Health News:Pharmacopeia Announces Senior Additions to Management Team 3Health News:Pharmacopeia Announces Senior Additions to Management Team 4Health News:China Bionanometer Industries Corporation Promotes New Cosmetics Product Line in China 2Health News:China Bionanometer Industries Corporation Promotes New Cosmetics Product Line in China 3Health News:NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results 2Health News:NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results 3Health News:NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results 4Health News:NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results 5Health News:NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results 6Health News:NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results 7Health News:NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results 8Health News:NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results 9Health News:NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results 10Health News:NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results 11Health News:NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results 12Health News:NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results 13Health News:NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results 14Health News:NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results 15Health News:NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results 16Health News:Life-Saving News for Battlefield Soldiers & Wounded Civilians 2Health News:Life-Saving News for Battlefield Soldiers & Wounded Civilians 3Health News:Blue Cross and Blue Shield Initiatives Recognized for Increasing Patient Safety and Efficiency 2Health News:Blue Cross and Blue Shield Initiatives Recognized for Increasing Patient Safety and Efficiency 3Health News:Blue Cross and Blue Shield Initiatives Recognized for Increasing Patient Safety and Efficiency 4Health News:Blue Cross and Blue Shield Initiatives Recognized for Increasing Patient Safety and Efficiency 5
(Date:11/24/2014)... 2014  Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage ... pain, announced today that Sergio Traversa , chief ... MICRO "MAIN Event" Micro-Cap Growth Conference on Wednesday, December ... Luxe Sunset Bel Air Hotel, which is located at ... . The presentation is scheduled for ...
(Date:11/24/2014)... , Nov. 24, 2014  AiCure, an artificial ... technology to monitor medication ingestion, has announced the ... and intervene with patients receiving medication as maintenance ... overdoses from prescription opiates have quadrupled in the ... per year than heroin, cocaine and benzodiazepines combined. ...
(Date:11/24/2014)... 24, 2014  GlySens Incorporated announced today that it ... from the National Institute of Diabetes and Digestive and ... of Health (NIH).  The grant is intended to support ... long term implantable glucose monitoring system.  Final preparations for ... expected to begin before the end of 2014. ...
Breaking Medicine Technology:Relmada Therapeutics To Present At LD MICRO Conference 2Can artificial intelligence solve the $55 billion problem of opioid abuse? 2GlySens Incorporated Awarded $2 Million Grant from the National Institutes of Health 2
... --  Empire Genomics today announced that it has ... portfolio for the Japanese market.  The deal represents Empire,s international ... "We are excited to have such a proven and expert ... access to our broad genomic product and service portfolio," said ...
... MYL ) today announced that its subsidiary Mylan Pharmaceuticals Inc. ... Administration (FDA) for its Abbreviated New Drug Application (ANDA) for ... mg, 15 mg, and 20 mg. This product is the ... which is indicated for the treatment of schizophrenia and the ...
Cached Medicine Technology:Empire Genomics Chooses Funakoshi as Japan Distributor 2Mylan Launches Generic Version of Zyprexa® Tablets 2
... spill-proof design and effective output, even when ... medical nebulizers are free-standing for easy preparation., ... available., ,All Portex® medication nebulizer products ... feature consistently fine misting and the efficient ...
... closed dilution nebulizer allows the clinician to deliver ... gas into the side port for precise high ... P31000N, for normal flow patients, delivers 8-12 lpm ... the side port. For your high flow needs, ...
... For use with metered dose inhalers., ... aerosolized medication from MDI canisters. Its versatile ... a ventilator circuit, in conjunction with an ... routine, oral inhalation. ACE may also be ...
Rotary Piston Mini Nebulizer...
Medicine Products: